Eagle Pharmaceuticals (EGRX) Competitors $0.55 -0.05 (-8.33%) (As of 12/20/2024 04:19 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends EGRX vs. LEXX, VYNE, ATNM, OCX, LTRN, ELEV, LUMO, MRKR, CALC, and TPSTShould you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include Lexaria Bioscience (LEXX), VYNE Therapeutics (VYNE), Actinium Pharmaceuticals (ATNM), OncoCyte (OCX), Lantern Pharma (LTRN), Elevation Oncology (ELEV), Lumos Pharma (LUMO), Marker Therapeutics (MRKR), CalciMedica (CALC), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical products" industry. Eagle Pharmaceuticals vs. Lexaria Bioscience VYNE Therapeutics Actinium Pharmaceuticals OncoCyte Lantern Pharma Elevation Oncology Lumos Pharma Marker Therapeutics CalciMedica Tempest Therapeutics Lexaria Bioscience (NASDAQ:LEXX) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk. Is LEXX or EGRX more profitable? Eagle Pharmaceuticals has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,249.14%. Eagle Pharmaceuticals' return on equity of 0.00% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Lexaria Bioscience-1,249.14% -86.10% -80.32% Eagle Pharmaceuticals N/A N/A N/A Which has more risk and volatility, LEXX or EGRX? Lexaria Bioscience has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Does the media refer more to LEXX or EGRX? In the previous week, Lexaria Bioscience had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 1 mentions for Lexaria Bioscience and 0 mentions for Eagle Pharmaceuticals. Lexaria Bioscience's average media sentiment score of 0.00 equaled Eagle Pharmaceuticals'average media sentiment score. Company Overall Sentiment Lexaria Bioscience Neutral Eagle Pharmaceuticals Neutral Do insiders and institutionals have more ownership in LEXX or EGRX? 13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 26.4% of Lexaria Bioscience shares are owned by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in LEXX or EGRX? Eagle Pharmaceuticals received 406 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 67.54% of users gave Eagle Pharmaceuticals an outperform vote. CompanyUnderperformOutperformLexaria BioscienceOutperform Votes6100.00% Underperform VotesNo VotesEagle PharmaceuticalsOutperform Votes41267.54% Underperform Votes19832.46% Which has better earnings and valuation, LEXX or EGRX? Eagle Pharmaceuticals has higher revenue and earnings than Lexaria Bioscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexaria Bioscience$464.28K83.83-$5.80M-$0.47-4.74Eagle Pharmaceuticals$257.55M0.03$35.64MN/AN/A Do analysts rate LEXX or EGRX? Lexaria Bioscience currently has a consensus target price of $11.00, suggesting a potential upside of 393.27%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryEagle Pharmaceuticals beats Lexaria Bioscience on 8 of the 15 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EGRX vs. The Competition Export to ExcelMetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.14M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5989.9717.18Price / Sales0.03195.801,116.21116.99Price / Cash0.1857.1642.8937.86Price / Book0.035.094.784.78Net Income$35.64M$151.83M$120.23M$225.60M7 Day Performance-26.67%-2.13%-1.92%-1.23%1 Month Performance-38.89%-3.10%11.49%3.36%1 Year Performance-89.02%11.54%30.57%16.60% Eagle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EGRXEagle Pharmaceuticals1.0078 of 5 stars$0.55-8.3%N/A-88.5%$7.14M$257.55M0.00134Gap DownLEXXLexaria Bioscience3.1515 of 5 stars$2.22-0.9%$11.00+395.5%+71.5%$38.75M$464,278.00-4.777VYNEVYNE Therapeutics2.6593 of 5 stars$2.60+1.6%$6.88+164.4%-3.8%$38.35M$493,000.00-2.9830News CoverageATNMActinium Pharmaceuticals1.252 of 5 stars$1.22-0.8%$7.40+506.4%N/A$38.07M$81,000.00-0.8849OCXOncoCyte3.2625 of 5 stars$2.26-2.6%$4.42+95.4%-22.1%$38.04M$1.50M0.00120Analyst ForecastGap DownLTRNLantern PharmaN/A$3.52+2.0%N/A-19.1%$37.96MN/A-1.9420Gap DownELEVElevation Oncology1.9868 of 5 stars$0.64+0.8%$7.20+1,023.2%+26.0%$37.90MN/A-0.7840Analyst ForecastLUMOLumos Pharma3.0946 of 5 stars$4.34flat$8.63+98.7%+44.2%$37.54M$2.21M-1.0130High Trading VolumeMRKRMarker Therapeutics4.0365 of 5 stars$4.19+2.9%$19.00+353.5%-1.3%$37.38M$3.31M0.0060News CoveragePositive NewsCALCCalciMedica2.9477 of 5 stars$2.76+1.1%$19.33+600.5%-10.1%$37.21MN/A-2.5330Positive NewsTPSTTempest Therapeutics1.8293 of 5 stars$0.84+5.0%$20.00+2,281.0%-80.7%$36.66MN/A0.0020 Related Companies and Tools Related Companies LEXX Alternatives VYNE Alternatives ATNM Alternatives OCX Alternatives LTRN Alternatives ELEV Alternatives LUMO Alternatives MRKR Alternatives CALC Alternatives TPST Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EGRX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EGRX Stock Alerts